secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001437749-23-006923
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions FY2022 revenue $161.8M (+36% YoY); GAAP net loss $139.8M on $110.4M impairment
--------------------------------------------------------------------------------

- Full year 2022 revenue $161.8M, up 36% vs 2021; biopreservation media revenue grew 45%.
- GAAP net loss $139.8M (includes $110.4M non-cash impairment of Stirling Ultracold intangible assets); adjusted net loss $29.3M.
- Adjusted EBITDA positive at $3.6M for full year; Q4 adjusted EBITDA $1.7M.
- Reaffirms 2023 revenue guidance of $188M-$202M, 16-25% growth; cell processing platform expected $89-93M (+30-35%).
- Cash and short-term investments $64.1M at year-end; Silicon Valley Bank operational with existing credit facilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/0001437749-23-006923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/bioli20230316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-006923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer